Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 63, Issue 18, 1704-1716
Copyright © 2006 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirk, M. B.
Right arrow Articles by Shirvani, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirk, M. B.
Right arrow Articles by Shirvani, J.

Clinical Reviews

Unlabeled uses of nebulized medications

Mary Beth Shirk, Kevin R. Donahue and Jill Shirvani

MARY BETH SHIRK, PHARM.D., is Specialty Practice Pharmacist, Critical Care, and Clinical Assistant Professor, Department of Pharmacy, The Ohio State University Medical Center (OSUMC), Columbus. KEVIN R. DONAHUE, B.S. and Pharm.D. degree candidate, is Pharmacy Intern, OSUMC. JILL SHIRVANI, A.A.S, is Registered Respiratory Therapist, OSUMC.

Address correspondence to Dr. Shirk at the Department of Pharmacy, The Ohio State University Medical Center, Room 368, Doan Hall, 410 West 10th Avenue, Columbus, OH 43210-1228 (marybeth.shirk{at}osumc.edu).


Purpose. The uses, dosing recommendations, benefits, and disadvantages of unlabeled drugs administered by nebulization are reviewed.

Summary. Nebulization is gaining popularity as a treatment alternative, and many drugs are used unlabeled in a nebulized form, including the opioids, lidocaine, magnesium sulfate, amphotericin B, and colistin. The opioids are frequently used to treat dyspnea in end-stage diseases. Common dosages include 1–2 mg every two hours as needed for hydromorphone and 25–50 µg every two hours for fentanyl citrate. Lidocaine can be used to relieve bronchoconstriction and cough symptoms as well as acting as a local anesthetic. It is typically given in a dose between 20 and 160 mg. Nebulized magnesium sulfate can be used in managing acute asthma and is given in dosages between 125 and 250 mg every 20 minutes, with no more than four consecutive doses. Nebulized amphotericin B can be used to prevent infections in immunocompromised patients. A typical amphotericin B regimen is 25 mg every 24 hours. Nebulized colistin is being studied in the prevention and treatment of gram-negative infections and in patients awaiting lung transplants. Colistin is often given as 75 mg every 12 hours to combat infections.

Conclusion. Unlabeled nebulization of opioids, lidocaine, magnesium, amphotericin B, and colistin is an alternative method of treatment for patients with pulmonary problems or infections or for those undergoing bronchoscopy. More research is needed to develop guidelines for their use since nebulization may provide benefits to many patients who otherwise cannot be treated or would be at risk of systemic adverse effects of the drugs.

Index terms: Aerosols; Amphotericin B; Anesthetics, local; Anticonvulsants; Antifungals; Antiinfective agents; Colistin; Dosage; Drug administration routes; Drug use; Fentanyl; Hydromorphone; Lidocaine; Magnesium sulfate; Nebulizers; Opiates; Protocols; Toxicity

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Health-System Pharmacists.